Carbohydrate-based drugs launched during 2000-2021.
10.1016/j.apsb.2022.05.020
- Author:
Xin CAO
1
;
Xiaojing DU
1
;
Heng JIAO
1
;
Quanlin AN
1
;
Ruoxue CHEN
1
;
Pengfei FANG
2
;
Jing WANG
2
;
Biao YU
2
Author Information
1. Zhongshan Hospital Institute of Clinical Science, Fudan University Shanghai Medical College, Shanghai 200032, China.
2. State Key Laboratory of Bio-organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China.
- Publication Type:Review
- Keywords:
Antibiotics;
Anticancer drug;
Antivirus drug;
Carbohydrate-based drug;
Glycoconjugate;
Glycodrug
- From:
Acta Pharmaceutica Sinica B
2022;12(10):3783-3821
- CountryChina
- Language:English
-
Abstract:
Carbohydrates are fundamental molecules involved in nearly all aspects of lives, such as being involved in formating the genetic and energy materials, supporting the structure of organisms, constituting invasion and host defense systems, and forming antibiotics secondary metabolites. The naturally occurring carbohydrates and their derivatives have been extensively studied as therapeutic agents for the treatment of various diseases. During 2000 to 2021, totally 54 carbohydrate-based drugs which contain carbohydrate moities as the major structural units have been approved as drugs or diagnostic agents. Here we provide a comprehensive review on the chemical structures, activities, and clinical trial results of these carbohydrate-based drugs, which are categorized by their indications into antiviral drugs, antibacterial/antiparasitic drugs, anticancer drugs, antidiabetics drugs, cardiovascular drugs, nervous system drugs, and other agents.
